Agenda

May 26-27, 2021 | Virtual Conference

Register Today
Print Friendly, PDF & Email
  • All
  • WEDNESDAY, MAY 26
  • THURSDAY, MAY 27
2:00 p.m. - 2:15 p.m.
AAM Chair’s Welcome and Introduction

Alok Sonig
CEO, US GenericsHead Global R&D & Biosimilars 
Lupin Pharmaceuticals, Inc.  

2:15 p.m. – 2:30 p.m.
Access! Award Presentation

The 2021 Champions of Access award honors those individuals and organizations who share AAM’s commitment to greater access to affordable, lifesaving and life sustaining medicines. We honor those who are similarly committed to ensuring that all patients can receive the medicine they need at a cost the system can bear.

2:30 p.m. – 3:00 p.m.
FDA Commissioner Keynote Address

With patient access to generic and biosimilar medicines a national priority, it is important to communicate the U.S. Department of Health and Human Service’s key initiatives for the generic and biosimilars industry. FDA’s Acting Commissioner will share the latest agency actions on quality initiatives, supply chain integrity, inspections during COVID-19, GDUFA III and BsUFA III and innovation in the generic and biosimilars industry. 

Janet Woodcock, M.D.
Acting Commissioner, Food and Drug Administration

3:00 p.m. – 4:30 p.m.
Securing the Pharmaceutical Supply Chain

An in-depth discussion with key industry leaders, U.S. government officials, and recognized experts on the steps needed to secure the generic and biosimilar pharmaceutical supply chain. We will discuss lessons from previous supply chain disruptions to help create a stronger and more resilient U.S. supply chain, with a particular focus on COVID-19. In addition, panelists will discuss how the United States can become an increasingly important link in the global supply chain.

Table Setter: Meredith Broadbent
Scholl Chair in International Business, Center for Strategic and International Studies

Moderator: Jonathan Kimball
Vice President, Trade & International Affairs, AAM

Kevin Cook
VP Supply Chain North America, ‎Novartis

Vinita Gupta
Chief Executive Officer, Lupin Limited

Chirag Patel
Co-CEO, Amneal Pharmaceuticals LLC

Ian Watson 
Deputy Assistant Secretary, Office of Strategy, Policy, Planning and Requirements (SPPR), U.S. Department Health and Human Services

4:30 p.m. – 5:30 p.m.
AAM Committee Meetings (members only)
4:30 p.m. – 5:30 p.m.
Access! 2021 Business Exposition
9:00 a.m. – 9:30 a.m.
State of AAM Address

Dan Leonard
President & CEO, AAM

9:30 a.m. – 10:00 a.m.
Keynote Address

Following enactment of a $1.9 trillion COVID-19 response and economic recovery package, the Biden administration and Congress will debate how to reduce reliance of the United States on the overseas supply chain, enhance domestic manufacturing and prepare the country for future public health emergencies. Health care and, in particular, lowering the cost of prescription drugs will also take center stage this year as lawmakers seek to complete work on the Lower Drug Costs Now Act (H.R. 3) and the Prescription Drug Pricing Reduction Act (Grassley-Wyden). This keynote address will provide insight on the current state of play and what to expect in the months ahead.

10:00 a.m. – 11:00 a.m.
Evolution and Disruption in Generic and Biosimilar Drug Channels

Join industry expert Adam J. Fein, PhD, as he helps you navigate this challenging and dynamic period in U.S. drug channels. During this interactive virtual session, Dr. Fein will explain the key trends reshaping U.S. drug channels, examine the emergence of organized market access channels, highlight business and marketing implications for generic and biosimilar medicines, and discuss strategic implications and the industry outlook. Dr. Fein will also be taking your questions during his session.

A message from Dr. Fein: https://www.youtube.com/watch?v=5D8qx1CQtfU

Adam Fein, PhD
President, Pembroke Consulting, Inc.
CEO, Pembroke’s Drug Channels Institute

11:00 a.m. – 11:30 a.m.
Networking Break
11:30 a.m. – 12:00 p.m.
COVID-19 Impact on Generics: Trends, Issues, & Outlook

Join industry expert Doug Long, MBA, as he explores the continuing impact of COVID-19 on the U.S. pharmaceutical market and generics and biosimilars specifically. Among issue Doug will explore are reduced diagnosis visits, shifts in sites of care, acute vs. chronic prescriptions, specialty vs. traditional prescriptions and the lack of a 2020-2021 flu season. Doug will also look ahead for the rest of 2021 and beyond. He will take your questions during the session.

Doug Long
Vice President, Industry Relations, IQVIA

12:00 p.m. – 1:30 p.m.
U.S. Biosimilar Market Access – Ensuring Current & Future Success

This panel will explore the current landscape for U.S. biosimilars. It will identify opportunities for policymakers to drive greater utilization and uptake under Medicare Part B, based in part on recent data revealing the impact of reimbursement rates and settings of care on prescriber behavior. The panel will look ahead to the coming expansion of biosimilars into Medicare Part D and discuss key policy changes that can encourage plans to promote their use.

Table Setter:

Pierre Boudrage 
Global Head of Biopharmaceuticals, Sandoz

Panelists:

Nick Adolph 
Associate Principal, IQVIA Market Access Strategy Consulting

John Brooks, JD 
Partner, South Capitol Consultants

Sean McGowan
Senior Director, Biosimilars, AmerisourceBergen

2:00 p.m. – 3:00 p.m.
AAM Committee Meetings (members only)
2:00 p.m. – 3:00 p.m.
Access! 2021 Business Exposition

*Agenda is subject to change

Get Started
& Register

Dividing Lines

Whether you are an AAM member, general attendee, or exhibitor, come meet the leaders and decision-makers who are determining the future of generics and biosimilars.

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

Access 2021 will use the information you provide on this form to be in touch with you and to provide updates and marketing.

Get Started
& Register

Dividing Lines

Whether you are an AAM member, general attendee, or exhibitor, come meet the leaders and decision-makers who are determining the future of generics and biosimilars.

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

Access 2021 will use the information you provide on this form to be in touch with you and to provide updates and marketing.
Skip to content